Chronic HDV occurs only with HBV and confers markedly higher risks of rapid progression, cirrhosis, liver failure, and ...

May 22 (Reuters) - Gilead Sciences said on Friday that its experimental drug for a rare and deadly liver infection that had ...

FDA approves 1st chronic HDV treatment Hepcludex to reduce virus levels and improve liver function in adults with hepatitis delta virus.

Vir Biotechnology recently announced it will present data from its Phase 2 SOLSTICE trial of the tobevibart-elebsiran combination for chronic hepatitis delta at the EASL Congress 2026 in Barcelona, ...

Chronic HDV is considered the most severe form of viral hepatitis. ・Bulevirtide 2 mg is also approved for use in the European Economic Area (EEA). ・Gilead Sciences concluded the acquisition of Germany ...

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated ...

Food and Drug Administration ‌said on Friday it ‌approved Gilead Sciences' drug for a ​rare and deadly liver infection that ...

US FDA grants accelerated approval to Gilead’s Hepcludex for the treatment of chronic hepatitis delta virus: Foster City, California Tuesday, May 26, 2026, 10:00 Hrs [IST] Gilea ...

Findings showed patients treated with brelovitug achieved 100% virologic response on all dosing arms. The Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to brelovitug ...

Investigational bulevirtide (Hepcludex) was effective and well tolerated in patients with chronic hepatitis delta virus (HDV), a researcher reported. In an interim analysis of the ongoing phase III ...

Findings showed 100% of participants taking the tobevibart and elebsiran combination achieved an undetectable HDV RNA at week 24 that was sustained through week 60. The Food and Drug Administration ...

This story is part of our series on viroids and virusoids, small infectious RNAs. The story is also the second installment in a series on hepatitis D virus, a virusoid-like pathogen that causes ...